Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)
Close on Nov 17, 2026Market cap $9.75BP/E –Yield –
Madrigal Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Madrigal Pharmaceuticals's EV/EBITDA was 2.0× on Feb 28, 2011.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2011 | Feb 28, 2011 | 2.0× | +0.4 |
| 2010 | Dec 31, 2010 | 1.5× | – |
See a number that looks wrong?